Pheon has a very strong leadership team of specialists, bringing together the best of clinical and managerial expertise with a proven track record in targeted oncology therapies and ADCs.
Dr. Arvin Yang is a seasoned CMO who joins Pheon Therapeutics with over a decade of experience in leading therapeutic oncology products through early-stage clinical development, and late-stage global registration trials at both Bristol Myers Squibb and Mersana Therapeutics.
At Mersana Therapeutics, Dr. Yang oversaw the clinical development of multiple novel assets in both early and late-stage global development. Prior to his work at Mersana, Dr. Yang spent over a decade at Bristol Myers Squibb, in a variety of leadership roles, making contributions that spanned all stages of the development process, from discovery through late-stage clinical trials and approvals. His work included generating clinical development plans and driving the approvals of nivolumab, ipilimumab, fedratinib, and luspatercept.
Dr. Yang earned his MD and PhD from Rutgers Robert Wood Johnson Medical School, training in internal medicine at Beth Israel Deaconess, Harvard Medical School, and in oncology at Memorial Sloan-Kettering Cancer Center. He has been published extensively in medical academic journals and is recognized as a leading authority in the fields of hematology and oncology.